{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T20:32:04Z","timestamp":1783542724991,"version":"3.55.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T00:00:00Z","timestamp":1586217600000},"content-version":"vor","delay-in-days":37,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicine in Drug Discovery"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.medidd.2020.100037","type":"journal-article","created":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T11:19:31Z","timestamp":1586776771000},"page":"100037","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Target Virus or Target Ourselves for COVID-19 Drugs Discovery?\u2015Lessons learned from anti-influenza virus therapies"],"prefix":"10.1016","volume":"5","author":[{"given":"Jiayu","family":"Liao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Way","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul","family":"Madahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medidd.2020.100037_bb0005","unstructured":"World Health Organization.Coronavirus disease (COVID-19) outbreak. https:\/\/www.who.int."},{"key":"10.1016\/j.medidd.2020.100037_bb0010","unstructured":"COVID-19 CORONAVIRUS PANDEMIC. https:\/\/www.worldometers.info\/coronavirus\/."},{"key":"10.1016\/j.medidd.2020.100037_bb0015","unstructured":"(COVID-19), C. D. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/cases-updates\/index.html."},{"key":"10.1016\/j.medidd.2020.100037_bb0020","unstructured":"Emergencies preparedness, r. https:\/\/www.who.int\/csr\/don\/en\/."},{"key":"10.1016\/j.medidd.2020.100037_bb0025","unstructured":"FDA, R.-. https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=490515."},{"key":"10.1016\/j.medidd.2020.100037_bb0030","unstructured":"FDA, C.-. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&varApplNo=006002."},{"key":"10.1016\/j.medidd.2020.100037_bb0035","unstructured":"development, A. u. g. t. t. c. d. a. v. i. https:\/\/www.statnews.com\/2020\/03\/19\/an-updated-guide-to-the-coronavirus-drugs-and-vaccines-in-development\/."},{"key":"10.1016\/j.medidd.2020.100037_bb0040","unstructured":"CDC. https:\/\/www.cdc.gov\/flu\/about\/burden\/2018-2019.html."},{"key":"10.1016\/j.medidd.2020.100037_bb0045","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1128\/AAC.01339-05","article-title":"Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use","volume":"50","author":"Monto","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medidd.2020.100037_bb0050","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1128\/AAC.00555-08","article-title":"Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008","volume":"52","author":"Sheu","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medidd.2020.100037_bb0055","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1001\/jama.2009.294","article-title":"Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States","volume":"301","author":"Dharan","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.medidd.2020.100037_bb0060","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1089\/mdr.2015.0297","article-title":"Drug-Resistant and Genetic Evolutionary Analysis of Influenza Virus from Patients During the 2013 and 2014 Influenza Season in Beijing","volume":"23","author":"Li","year":"2017","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.medidd.2020.100037_bb0065","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1743-422X-7-53","article-title":"A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir","volume":"7","author":"Matsuzaki","year":"2010","journal-title":"Virol J"},{"key":"10.1016\/j.medidd.2020.100037_bb0070","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.coph.2016.08.003","article-title":"Antiviral therapies on the horizon for influenza","volume":"30","author":"Naesens","year":"2016","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.medidd.2020.100037_bb0075","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ejphar.2017.05.038","article-title":"New drug-strategies to tackle viral-host interactions for the treatment of influenza virus infections","volume":"809","author":"van de Wakker","year":"2017","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.medidd.2020.100037_bb0080","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1126\/science.278.5344.1803","article-title":"Specific Inhibition of Stat3 Signal Transduction by PIAS3","volume":"278","author":"Chung","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.medidd.2020.100037_bb0085","unstructured":"Liao, J. Protein Inhibitors of Activated Stat. Ph.D. Thesis, University of Californai, Los Angeles (1999)."},{"key":"10.1016\/j.medidd.2020.100037_bb0090","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1039\/c2mb05465e","article-title":"Systematic determinations of SUMOylation activation intermediates and dynamics by a sensitive and quantitative FRET assay","volume":"8","author":"Song","year":"2012","journal-title":"Mol Biosyst"},{"key":"10.1016\/j.medidd.2020.100037_bb0095","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1128\/JVI.06227-11","article-title":"Human pathogens and the host cell SUMOylation system","volume":"86","author":"Wimmer","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.medidd.2020.100037_bb0100","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrg2323","article-title":"Rates of evolutionary change in viruses: patterns and determinants","volume":"9","author":"Duffy","year":"2008","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.medidd.2020.100037_bb0105","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1073\/pnas.90.9.4171","article-title":"Rates of spontaneous mutation among RNA viruses","volume":"90","author":"Drake","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.medidd.2020.100037_bb0110","doi-asserted-by":"crossref","first-page":"270","DOI":"10.4161\/rna.8.2.15013","article-title":"Coronaviruses: an RNA proofreading machine regulates replication fidelity and diversity","volume":"8","author":"Denison","year":"2011","journal-title":"RNA Biol"},{"key":"10.1016\/j.medidd.2020.100037_bb0115","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.antiviral.2014.07.014","article-title":"Nitazoxanide: a first-in-class broad-spectrum antiviral agent","volume":"110","author":"Rossignol","year":"2014","journal-title":"Antiviral Res"},{"key":"10.1016\/j.medidd.2020.100037_bb0120","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.virol.2014.05.015","article-title":"Nitazoxanide, an antiviral thiazolide, depletes ATP-sensitive intracellular Ca(2+) stores","volume":"462-463","author":"Ashiru","year":"2014","journal-title":"Virology"}],"container-title":["Medicine in Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590098620300245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590098620300245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T01:38:19Z","timestamp":1762911499000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590098620300245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":24,"alternative-id":["S2590098620300245"],"URL":"https:\/\/doi.org\/10.1016\/j.medidd.2020.100037","relation":{"has-review":[{"id-type":"doi","id":"10.14322\/publons.r7761564","asserted-by":"object"}]},"ISSN":["2590-0986"],"issn-type":[{"value":"2590-0986","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Target Virus or Target Ourselves for COVID-19 Drugs Discovery?\u2015Lessons learned from anti-influenza virus therapies","name":"articletitle","label":"Article Title"},{"value":"Medicine in Drug Discovery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medidd.2020.100037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100037"}}